Skip to main content
Medesis Pharma S.A. logo

Medesis Pharma S.A. — Investor Relations & Filings

Ticker · ALMDP ISIN · FR0010844464 LEI · 969500C15M96P00UR648 PA Manufacturing
Open in API
Filings indexed 118 across all filing types
Latest filing 2021-12-02 Regulatory Filings
Country FR France
Listing PA ALMDP

About Medesis Pharma S.A.

https://www.medesispharma.com/

Medesis Pharma is a clinical-stage pharmaceutical biotechnology company focused on developing treatments for serious diseases using its proprietary AONYS® drug delivery platform. The AONYS® technology is a micro-emulsion designed for buccal (oral) administration, enabling the intracellular delivery of various therapeutic molecules, including metal ions, interfering RNAs, and peptides. A key feature of the platform is its ability to transport active ingredients across the blood-brain barrier, making it a promising approach for neurological disorders. The company's development pipeline addresses diseases with high unmet medical needs, including neurodegenerative conditions like Alzheimer's disease and therapies for individuals exposed to nuclear radiation.

Recent filings

Filing Released Lang Actions
MEDESIS PHARMA PRESENTE UN POSTER SCIENTIFIQUE AU CONGRES SUR LA THERAPIE GENIQUE POUR LE TRAITEMENT DES MALADIES NEUROLOGIQUES
Regulatory Filings Classification · 99% confidence The document is a press release dated December 2, 2021, announcing Medesis Pharma's participation in the 3rd Gene Therapy for Neurological Disorders Congress in Boston. It details the presentation of a poster by the Director of Medical Affairs regarding the Aonys® drug delivery technology for treating neurodegenerative diseases. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement about the company's presence and scientific contribution at an industry conference, which falls under general investor relations or corporate activity updates. Since it is an announcement about scientific/corporate activity rather than a specific financial report or mandatory filing, it best fits the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement, or potentially 'Investor Presentation' (IP) if it were the presentation itself, but here it is an announcement *about* presenting. Given the options, RNS serves as the best general corporate communication fallback for non-standard announcements.
2021-12-02 French
MEDESIS PHARMA PRESENTS A SCIENTIFIC POSTER AT THE CONGRESS ON GENE THERAPY FOR THE TREATMENT OF NEUROLOGICAL DISEASES
Regulatory Filings Classification · 95% confidence The document is a press release dated December 2, 2021, announcing Medesis Pharma's participation in the '3rd congress on therapy gene for neurological disorders' and detailing the poster presentation regarding their Aonys® technology. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement about the company's presence and scientific contribution at an industry conference. This type of announcement, which informs investors about scientific/industry engagement, often falls under general investor relations communication. Since there is no specific category for 'Conference Participation Announcement,' and it is not a formal financial report, a management change, or a transaction report, the most appropriate general category is 'Regulatory Filings' (RNS) as a catch-all for non-standard corporate news releases, or potentially 'Investor Presentation' (IP) if the content were the presentation itself, but here it is an announcement *about* participation. Given the nature of informing the market about scientific updates and conference attendance, RNS is the best fit as a general corporate communication.
2021-12-02 English
MEDESIS PHARMA : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital), referencing Article 223-16 of the AMF General Regulation. This structure strongly indicates a mandatory regulatory disclosure regarding the total number of shares and voting rights, which is typically filed monthly or periodically. This type of filing is not explicitly covered by the specific codes like 10-K, ER, or IR. Since it is a formal regulatory disclosure that doesn't fit the other specific categories (like Director's Dealing, Dividend Notice, or Capital Change), the most appropriate fallback category is Regulatory Filings (RNS). The document is short and contains structured data about the capital structure, confirming it is a specific regulatory report, not just an announcement of a report.
2021-12-01 French
TREATMENT FOR SEVERE FORMS OF COVID-19: MEDESIS PHARMA’S PHASE II CLINICAL TRIAL APPROVED BY THE BRAZILIAN HEALTH AUTHORITIES
Regulatory Filings Classification · 100% confidence The document is a press release dated November 22, 2021, announcing that Medesis Pharma has received approval to conduct a Phase II clinical trial for its NanoManganese® program in Brazil for severe COVID-19 treatment. This type of announcement, detailing clinical trial progress, regulatory milestones, and future expectations, is characteristic of an Earnings Release (ER) or a general corporate update. Since it is not a full financial report (10-K or IR), a transcript (CT), or a specific management discussion (MDA), and it focuses on operational/clinical progress rather than just management changes (MANG) or financing (CAP), it fits best as an Earnings Release (ER) which often includes operational highlights, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the structure as a news announcement detailing a significant operational event (clinical trial approval), ER is the most appropriate fit among the provided options, as ERs frequently contain key operational updates alongside financial context (though financial context is minimal here). However, since it is a specific announcement about a clinical trial milestone, and not a periodic financial results summary, it is closer to a general corporate announcement. If we strictly follow the definitions, it is an announcement of a significant corporate/operational event. Since it is not a formal regulatory filing like a 10-K or IR, and it's not a presentation (IP) or a management discussion (MDA), it functions as a key update. Given the options, ER (Earnings Release) often encompasses major operational news released around reporting periods, but this is a standalone clinical update. Let's re-evaluate against the options. It is not a DIV, DIRS, DVA, or DEF 14A. It is a specific announcement about clinical progress. This type of announcement often falls under RNS (Regulatory Filings) if it's a mandatory disclosure, or ER if it's part of the regular communication cadence. Since it is a specific, non-financial regulatory/clinical update, RNS is a strong candidate as a general regulatory announcement. However, if we consider the context of corporate communication, major clinical trial updates are often bundled with ERs. Given the lack of explicit financial results, RNS (Regulatory Filings / General Announcement) is the safest fallback for a specific, non-standard corporate event announcement. Let's check if it fits better elsewhere. It is not a LTR (Legal Proceedings Report). It is not an IP (Investor Presentation). It is a press release announcing a clinical trial approval. This is a common type of announcement that often gets classified as RNS when it doesn't fit a more specific operational category like M&A (TAR) or Capital Change (CAP). I will classify it as RNS as it is a general regulatory/corporate announcement not covered by the more specific codes.
2021-11-22 English
TRAITEMENT DES FORMES GRAVES DU COVID-19 : L’ÉTUDE CLINIQUE DE PHASE II DE MEDESIS PHARMA AUTORISÉE PAR LES AUTORITES DE SANTÉ AU BRESIL
Regulatory Filings Classification · 100% confidence The document is a press release dated November 22, 2021, announcing that Medesis Pharma has received authorization to conduct a Phase II clinical trial for its NanoManganese program in Brazil for severe COVID-19 treatment. This type of announcement, detailing clinical trial progress, regulatory milestones, and future expectations, is characteristic of corporate communications aimed at investors and the public regarding ongoing development programs. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a full interim report (IR). Since it details specific development progress and is a general corporate update, it fits best under the broad category of Investor Presentation (IP) if it were a slide deck, or more generally as a Regulatory Filing (RNS) if it doesn't fit other specific categories. However, given the content focuses heavily on R&D progress and clinical trial updates, it is often classified as an Investor Presentation (IP) if it were a presentation, but as a general corporate update/press release about development, it often defaults to RNS or sometimes falls under a general 'Corporate Information' category not explicitly listed. Since the document is a press release detailing clinical trial progress and development strategy, and does not fit the specific definitions for ER, IR, AR, or CAP, the most appropriate general category for significant corporate news that isn't a mandatory financial report is RNS (Regulatory Filings/General Announcement). It is too detailed for a simple RPA.
2021-11-22 French
MEDESIS PHARMA : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 31 octobre 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and references Article 223-16 of the AMF General Regulation. It explicitly provides a table showing the total number of shares and voting rights as of a specific date (October 31, 2021). This content directly relates to the structure of the company's capital and voting rights, which is a specific type of regulatory disclosure. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the closest fit as it deals with the total number of shares and voting rights, which are fundamental components of capital structure changes or reporting. However, since this is a recurring monthly report on the total capital structure, and not necessarily a specific 'issue' or 'change' announcement, it could also fall under a general regulatory filing (RNS). Given the specific nature of reporting total shares and voting rights, which is often mandated alongside capital changes or as a standalone disclosure, SHA is a strong candidate, but 'DIRS' (Director's Dealing) and 'MRQ' (Major Shareholding Notification) are incorrect. 'SHA' covers capital changes, and this is a capital structure report. Let's re-evaluate the definitions. None perfectly match a 'Total Voting Rights Report'. However, 'SHA' (Share Issue/Capital Change) is the most relevant category dealing with the number of shares. If this were a notification of a change in a major shareholder, it would be MRQ. Since it is the total capital count, it relates to the overall share structure. In many contexts, this type of filing is categorized under capital structure updates. Given the options, SHA is the best fit for reporting the total share count, even if it's a routine update rather than a specific 'issue'. If SHA is too narrow, RNS (Regulatory Filings) is the fallback. Since the content is highly specific to the share count, I will classify it as SHA, as it pertains to the capital structure.
2021-11-09 French

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.